Pfizer’s Gene Therapy for Hemophilia A Succeeds in Late-Stage Trial
Pfizer’s gene therapy for a rare genetic blood-clotting disorder called hemophilia A has been successful in late-stage trials, paving the way for potential approval. Hemophilia A is a lifelong disease caused by a lack of factor VIII protein. Without enough of this protein, blood cannot clot properly, increasing the risk of bleeding episodes. The condition … Read more